Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Bruker Corporation has an average analyst rating of "Hold" from 16 covering analysts, with a mix of sell, hold, buy, and strong buy recommendations. The consensus 12-month price target is about $56.79.
• Several analysts recently adjusted their views, including Citigroup and Barclays raising price targets to $60, while Barclays maintained an overweight rating and Wall Street Zen upgraded the stock to buy.
• The company reported better-than-expected quarterly results, posting EPS of $0.31 versus $0.23 expected and revenue of $823.4 million versus $795.6 million expected. Bruker also paid a quarterly dividend of $0.05 per share, though its dividend yield remains modest at 0.3%.

Shares of Bruker Corporation (NASDAQ:BRKR - Get Free Report) have been given an average rating of "Hold" by the sixteen analysts that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, six have given a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $56.7857.

Several equities research analysts have recently weighed in on the stock. Citigroup upped their target price on shares of Bruker from $44.00 to $60.00 and gave the stock a "neutral" rating in a report on Wednesday, July 8th. Stifel Nicolaus set a $45.00 price target on shares of Bruker in a report on Friday, May 8th. Weiss Ratings raised Bruker from a "sell (d)" rating to a "sell (d+)" rating in a report on Wednesday, June 3rd. Wall Street Zen upgraded Bruker from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Finally, Barclays raised their price target on Bruker from $53.00 to $60.00 and gave the company an "overweight" rating in a report on Wednesday, June 24th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Orbis Allan Gray Ltd acquired a new position in shares of Bruker during the second quarter worth approximately $192,735,000. Price T Rowe Associates Inc. MD grew its stake in shares of Bruker by 2,963.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock valued at $111,488,000 after purchasing an additional 2,289,269 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after purchasing an additional 1,850,215 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company's stock valued at $108,796,000 after purchasing an additional 1,756,460 shares in the last quarter. Finally, Millennium Management LLC raised its position in Bruker by 222.6% in the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company's stock worth $86,663,000 after purchasing an additional 1,269,316 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Price Performance

Bruker stock opened at $60.45 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The company has a market capitalization of $9.20 billion, a PE ratio of -251.88, a price-to-earnings-growth ratio of 1.94 and a beta of 1.29. Bruker has a one year low of $28.53 and a one year high of $64.54. The business has a 50 day simple moving average of $56.32 and a 200 day simple moving average of $46.32.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm had revenue of $823.40 million for the quarter, compared to analysts' expectations of $795.62 million. During the same period in the prior year, the business posted $0.47 earnings per share. The business's revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, sell-side analysts forecast that Bruker will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were paid a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker's dividend payout ratio (DPR) is -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.